Study of resistance to chemotherapy mediated by ABC transporters in biopsies of glioblastoma multiforme;Glioblastoma multiforme y estudio de la resistencia a la quimioterapia mediada por transportadores ABC

Revista Medica de Chile

Volumn 139, Issue 4, 2011, Pages 415-424

  Quezada, Claudia ^a   Peigñan, Lilia ^a   Segura, Rodrigo ^b   Riquelme, Francisco ^b   Melo, Rómulo ^b   David Rojas, Z ^b   Ayach, Freddy ^b   Martín, Rody San ^a   Cárcamo, Juan Guillermo ^a  

^a UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^b Neurocritical Care Service   (Chile)

Author keywords

Drug resistance, neoplasm; Glioblastoma; Multidrug resistanceassociated proteins

Indexed keywords

ABC TRANSPORTER; TUMOR PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN TUMOR; CHILD; COHORT ANALYSIS; DRUG RESISTANCE; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; TUMOR CELL CULTURE;

ADOLESCENT; ADULT; AGED; ATP-BINDING CASSETTE TRANSPORTERS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 79960555749     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: 10.4067/S0034-98872011000400001     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. Cancer J Clin 2008; 58: 71-96.
2. Díaz V, Yáñez A, Ponce C, Villegas, Pasten J. Tendencia de la mortalidad por tumores cerebrales malignos en Chile. Análisis de tasas. Rev Chil Neuro-Psiquiat 2006; 44: 263-70.
3. Sawyer A, Piepmeier J, Saltzman W. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J Biol Med 2006; 79: 141-52.
4. Brandes MM. State-of-the-art treatment of high-grade brain tumors. Semin Oncol 2003; 30 (6 Suppl 19): 4-9.
5. Valera E, Lucio-Eterovic A, Neder L, Scrideli C, Machado H, Carlotti-Junior C, et al. Quantitative PCR analysis of the expression profile of genes related to multiple drug resistance in tumors of the central nervous system. J Neurooncol 2007; 85: 1-10.
6. Mladkova N, Chakravarti A. Molecular Profi{ligature}ling in Glioblastoma: Prelude to Personalized Treatment. Current Oncology Reports 2009; 11: 53-61.
7. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008; 9: 105-27.
8. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005; 6: 591-602.
9. Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007; 25: 2295-305.
10. Bredel M, Zentner J. Brain-tumour drug resistance: the bare essentials. Lancet Oncology 2002; 3: 397-406.
11. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-34.
12. Calatozzolo C, Gelati M, Ciusani E, Sciacca FL, Pollo B, Cajola L, et al. Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5and GST-pi in human glioma. J Neurooncol 2005; 74: 113-21.
13. Decleves X, Amiel A, Delattre JY, Schermann JM. Role of ABC transporters in the chemoresistance of human gliomas. Curr Cancer Drug Targets 2006; 6: 433-45.
14. Matsumoto Y, Miyakei K, Kunishio K, Tamiya T, Seigo N. Reduction of expression of the multidrug resistance protein (MRP) 1 in glioma cells by antisense phosphorothioate oligonucleotides. J Med Invest 2004; 51: 194-201.
15. Quezada C, Garrido W, González-Oyarzún M, Rauch MC, Salas M, San Martín R, et al. Effect of tacrolimus on activity and expression of Pgp and ABCA5 proteins in hematoencephalic barrier cells. Biol Pharm Bull 2008; 31: 1911-6.
16. Valladares D, Quezada C, Montecinos P, Concha II, Yáñez AJ, Sobrevia L, et al. Adenosine A(2B) receptor mediates an increase on VEGF-A production in rat kidney glomeruli. Biochem Biophys Res Commun 2008; 366: 180-5.
17. Van Der Deen M, Homan S, Timmer-Bosscha H, Scheper R, Timens W, Postma D, et al. Effect of COPD treatments on MRP1-mediated transport in bronchial epithelial cells. Int J Chron Obstruct Pulmon Dis 2008; 3: 469-75.
18. Gekeler V, Ise W, Sanders KH, Ulrich WR, Beck J. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 1995; 208: 45-52.
19. Lu C, Shervington A. Chemoresistance in gliomas. Mol Cell Biochem 2008; 312: 71-80
20. Stupp R, van den Bent MJ, Hegi ME. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 2005; 5: 198-206.
21. 6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008; 26: 4189-99.
22. 6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol 2007; 37: 897-906.
23. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neurooncología (GICNO). Br J Cancer 2006; 95: 1155-60.
24. Motomura K, Natsume A, Kishida Y, Higashi H, Kondo Y, Nakasu Y, et al. Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: a multicenter study. Cancer 2010.
25. van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 2009; 27: 5881-6.
26. Lee SW, Kim WJ, Park JA, Choi YK, Kwon YW, Kim KW. Blood-brain barrier interfaces and brain tumors. Arch Pharm Res 2006; 29: 265-75.
27. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57: 173-185.
28. O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, et al. Crown J. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother. Pharmacol 2007; 59: 79-87.
29. Peck RA, Hewett J, Harding MW. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 2001; 19: 3130-41.
30. Robey RW, Shukla S, Finley EM. Inhibition of P-glycoprotein (ABCB1)-and multidrug resistance-associated protein 1 (ABC1)-mediated transport by the orally administered inhibitor, CB T-1(R). Biochem Pharmacol 2008; 75:1302-1312.
31. Peak SJ, Levin VA. Role of bevacizumab therapy in the management of glioblastoma. Cancer Manag Res 2010; 2: 97-104.